Nov 3, 2016 Syros Pharmaceuticals to Present New Data on SY-1425, Its First-in-Class Potent and Selective RARα Agonist, at the ASH Annual Meeting
Oct 11, 2016 Syros Announces Approval of Investigational Device Exemption (IDE) for Blood Test to Identify Cancer Patients with Proprietary Biomarkers
Sep 22, 2016 Syros Announces First Patient Enrolled in Phase 2 Clinical Trial of SY-1425 in Genomically Defined Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome
Aug 29, 2016 Syros’ Scientific Founders Publish on First Selective CDK12 and CDK13 Inhibitor as Promising Approach for Treatment of Cancer
Aug 15, 2016 Syros Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update
Jul 6, 2016 Syros Pharmaceuticals Announces Closing of Initial Public Offering, Including Full Exercise of Option to Purchase Additional Shares
